On Friday, Shares of Veeva Systems Inc (NYSE:VEEV), lost -6.48% to $27.12.
Sobi, a specialty life sciences company dedicated to rare diseases, has selected Veeva Commercial Cloud to support its global commercial organisation across sales, marketing, and medical. A complete solution, Veeva Commercial Cloud brings together customer data, multichannel interactions, and compliant content to provide a comprehensive view of customers for more efficient and effective commercial execution.
Veeva Commercial Cloud comprises Veeva CRM to orchestrate customer engagement across channels, Veeva Vault PromoMats for promotional materials administration, Veeva Network customer master data administration software, and Veeva OpenData for customer data. It all works in concert to enable timely, compliant, and personalised customer interactions.
Veeva Systems Inc. provides cloud-based software solutions for the life sciences industry in North America, Europe, the Asia Pacific, and Latin America.
Shares of Groupon Inc (NASDAQ:GRPN), declined -0.39% to $ 6.38, during its last trading session.
Groupon, declared that Jason Child, Chief Financial Officer, and Rich Williams, President of North America, will present at the Bank of America Merrill Lynch 2015 Global Technology Conference in San Francisco on Wednesday, June 3 at 10:45 a.m. Pacific Daylight Time.
Groupon, Inc. operates online local commerce marketplaces that connect merchants to consumers by offering goods and services at a discount worldwide. It also offers deals on products for which it acts as the merchant of record.
At the end of Friday’s trade, Shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), gained 1.03% to $ 0.2930.
AEterna Zentaris, declared that it has received written scientific advice from the European Medicines Agency regarding the further development plan, counting the study design, for the new confirmatory Phase 3 clinical study of Macrilen (macimorelin) for use in evaluating adult growth hormone deficiency, following a Scientific Advice Meeting that was held earlier this month. As a result of the advice, the Company believes that the confirmatory Phase 3 study that was discussed with the U.S. Food & Drug Administration last March, meets the EMA’s study-design expectations.
Dr. Richard Sachse, Chief Scientific Officer and Chief Medical Officer of the Company stated, “We are very happy with the EMA’s advice as we continue to believe that our trial will confirm the efficacy and safety of this product. In principle, the EMA agreed with our projected protocol design in the evaluation of the product. In addition, it projected that we consider additional aspects regarding the demonstration of reproducibility of a diagnosis made using Macrilen, which will further enhance the profile of our compound. We believe we will be able to provide the information that EMA requires in a timely and cost‑effective manner.”
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health.
Finally, U.S. Geothermal Inc. (NYSEMKT:HTM), ended its last trade with 6.19% gain, and close at $ 0.5150.
U.S. Geothermal, is happy to declare that Jonathan Zurkoff, Executive Vice President Finance and Treasurer, will be a featured presenter at the 2015 LD Micro Conference in Los Angeles on June 2, 2015 at the Luxe Hotel. The Company’s presentation is planned to start at 2:30 p.m.
U.S. Geothermal, Inc. constructs, manages, and operates power plants that utilize geothermal resources in the Western United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
